Center for Scientific Review; Notice of Closed Meetings, 76484-76485 [2024-21150]

Download as PDF 76484 Federal Register / Vol. 89, No. 181 / Wednesday, September 18, 2024 / Notices regarding the roles and responsibilities of sponsors, investigators, healthcare institutions, and local healthcare providers and addresses using a quality by design approach to facilitate the conduct of trials in the clinical practice setting. This draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on ‘‘Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice.’’ It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. II. Paperwork Reduction Act of 1995 While this guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3521). The collections of information in 21 CFR parts 50 and 56 have been approved under OMB control number 0910–0130; the collections of information in 21 CFR part 312 have been approved under OMB control number 0910–0014; the collections of information in 21 CFR part 314 have been approved under OMB control number 0910–0001; and the collections of information in 21 CFR part 601 have been approved under OMB control number 0910–0338. III. Electronic Access khammond on DSKJM1Z7X2PROD with NOTICES Persons with access to the internet may obtain the draft guidance at https:// www.fda.gov/drugs/guidancecompliance-regulatory-information/ guidances-drugs, https://www.fda.gov/ vaccines-blood-biologics/guidancecompliance-regulatory-informationbiologics/biologics-guidances, https:// www.fda.gov/regulatory-information/ search-fda-guidance-documents, or https://www.regulations.gov. Dated: September 12, 2024. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2024–21077 Filed 9–17–24; 8:45 am] BILLING CODE 4164–01–P VerDate Sep<11>2014 17:11 Sep 17, 2024 Jkt 262001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Cohort Studies of HIV/AIDS and Substance Use. Date: November 4, 2024. Time: 10:00 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 594–9460, Soyoun.cho@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services. Date: November 6, 2024. Time: 11:30 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Marisa Srivareerat, Ph.D., Scientific Review Officer, Scientific Review Branch, Office of Extramural Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 435–1258, marisa.srivareerat@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders. Date: November 13, 2024. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Devon Rene Oskvig, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 402–6965, devon.oskvig@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: September 12, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–21152 Filed 9–17–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Oncology 1—Basic Translational Integrated Review Group; Basic Mechanisms of Cancer Health Disparities Study Section. Date: October 15–16, 2024. Time: 10:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Amy L Rubinstein, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5152, MSC 7844, Bethesda, MD 20892, 301–408– 9754, email: rubinsteinal@csr.nih.gov. Name of Committee: Oncology 2— Translational Clinical Integrated Review E:\FR\FM\18SEN1.SGM 18SEN1 khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 89, No. 181 / Wednesday, September 18, 2024 / Notices Group; Translational Immuno-oncology Study Section. Date: October 16–17, 2024. Time: 8:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency, Bethesda, One Bethesda Metro Center, Bethesda, MD 20814 (In Person). Contact Person: Maria Elena CardenasCorona, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817, 301–867–5309, email: maria.cardenas-corona@nih.gov. Name of Committee: Bioengineering Sciences & Technologies Integrated Review Group; Drug and Biologic Therapeutic Delivery Study Section. Date: October 16–17, 2024. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: St. Gregory Hotel, 2033 M Street NW, Washington, DC 20036 (In Person). Contact Person: Janice Duy, Ph.D., Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, 301–594–3139, email: janice.duy@nih.gov. Name of Committee: Musculoskeletal, Oral and Skin Sciences Integrated Review Group; Musculoskeletal Rehabilitation Sciences Study Section. Date: October 16–17, 2024. Time: 9:00 a.m. to 9:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Richard Michael Lovering, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1000J, Bethesda, MD 20892, (301) 867–5309, email: loveringrm@mail.nih.gov. Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Social and Environmental Determinants of Health Study Section. Date: October 16–17, 2024. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814 (In Person). Contact Person: Ananya Paria, MPH, MS, DHSC, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1007H, Bethesda, MD 20892, (301) 827–6513, email: pariaa@mail.nih.gov. Name of Committee: Social and Community Influences on Health Integrated Review Group; Health Promotion in Communities Study Section. Date: October 16–17, 2024. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Helena Eryam Dagadu, MPH, Ph.D., Scientific Review Officer, Center VerDate Sep<11>2014 18:02 Sep 17, 2024 Jkt 262001 for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3137, Bethesda, MD 20892, (301) 435–1266, email: dagaduhe@csr.nih.gov. Name of Committee: Interdisciplinary Molecular Sciences and Training Integrated Review Group; Cellular and Molecular Technologies Study Section. Date: October 16–17, 2024. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Tatiana V Cohen, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5213, Bethesda, MD 20892, 301–455–2364, email: tatiana.cohen@nih.gov. Name of Committee: Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Biochemistry and Biophysics of Membranes Study Section. Date: October 16–17, 2024. Time: 9:30 a.m. to 8:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: James W Mack, Ph.D., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4154, MSC 7806, Bethesda, MD 20892, (301) 435– 2037, email: mackj2@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Academic-Industrial Partnerships for Translation of Technologies. Date: October 16, 2024. Time: 10:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Jennifer Ann Sanders, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–3553, email: jennifer.sanders@nih.gov. Name of Committee: Cell Biology Integrated Review Group; Biology and Development of the Eye Study Section. Date: October 16–17, 2024. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Robert O’Hagan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 909–6378, email: ohaganr2@ csr.nih.gov. Name of Committee: Infectious Diseases and Immunology A Integrated Review Group; Bacterial Virulence Study Section. Date: October 16–17, 2024. PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 76485 Time: 10:00 a.m. to 9:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Susan Daum, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3202, Bethesda, MD 20892, 301–827–7233, email: susan.boyle-vavra@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; BRAIN Initiative: Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS. Date: October 16, 2024. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Aurea D De Sousa, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5186, Bethesda, MD 20892, (301) 827–6829, email: aurea.desousa@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: September 12, 2024. Bruce A. George, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–21150 Filed 9–17–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Environmental Health Sciences; Notice of Closed Meetings Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Environmental Health Sciences Review Committee. E:\FR\FM\18SEN1.SGM 18SEN1

Agencies

[Federal Register Volume 89, Number 181 (Wednesday, September 18, 2024)]
[Notices]
[Pages 76484-76485]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21150]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Oncology 1--Basic Translational Integrated 
Review Group; Basic Mechanisms of Cancer Health Disparities Study 
Section.
    Date: October 15-16, 2024.
    Time: 10:00 a.m. to 8:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Amy L Rubinstein, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5152, MSC 7844, Bethesda, MD 
20892, 301-408-9754, email: [email protected].

    Name of Committee: Oncology 2--Translational Clinical Integrated 
Review

[[Page 76485]]

Group; Translational Immuno-oncology Study Section.
    Date: October 16-17, 2024.
    Time: 8:00 a.m. to 7:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency, Bethesda, One Bethesda Metro Center, 
Bethesda, MD 20814 (In Person).
    Contact Person: Maria Elena Cardenas-Corona, Ph.D., Scientific 
Review Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Bethesda, MD 20817, 301-867-5309, 
email: [email protected].

    Name of Committee: Bioengineering Sciences & Technologies 
Integrated Review Group; Drug and Biologic Therapeutic Delivery 
Study Section.
    Date: October 16-17, 2024.
    Time: 8:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: St. Gregory Hotel, 2033 M Street NW, Washington, DC 20036 
(In Person).
    Contact Person: Janice Duy, Ph.D., Scientific Review Officer, 
Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 
20892, 301-594-3139, email: [email protected].

    Name of Committee: Musculoskeletal, Oral and Skin Sciences 
Integrated Review Group; Musculoskeletal Rehabilitation Sciences 
Study Section.
    Date: October 16-17, 2024.
    Time: 9:00 a.m. to 9:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Richard Michael Lovering, Ph.D., Scientific 
Review Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 1000J, Bethesda, MD 20892, (301) 
867-5309, email: [email protected].

    Name of Committee: Population Sciences and Epidemiology 
Integrated Review Group; Social and Environmental Determinants of 
Health Study Section.
    Date: October 16-17, 2024.
    Time: 9:00 a.m. to 8:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 
20814 (In Person).
    Contact Person: Ananya Paria, MPH, MS, DHSC, Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 1007H, Bethesda, MD 20892, (301) 
827-6513, email: [email protected].

    Name of Committee: Social and Community Influences on Health 
Integrated Review Group; Health Promotion in Communities Study 
Section.
    Date: October 16-17, 2024.
    Time: 9:00 a.m. to 8:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Helena Eryam Dagadu, MPH, Ph.D., Scientific 
Review Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 3137, Bethesda, MD 20892, (301) 
435-1266, email: [email protected].

    Name of Committee: Interdisciplinary Molecular Sciences and 
Training Integrated Review Group; Cellular and Molecular 
Technologies Study Section.
    Date: October 16-17, 2024.
    Time: 9:00 a.m. to 8:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Tatiana V Cohen, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5213, Bethesda, MD 20892, 301-
455-2364, email: [email protected].

    Name of Committee: Biological Chemistry and Macromolecular 
Biophysics Integrated Review Group; Biochemistry and Biophysics of 
Membranes Study Section.
    Date: October 16-17, 2024.
    Time: 9:30 a.m. to 8:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: James W Mack, Ph.D., Scientific Review 
Administrator, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 4154, MSC 7806, Bethesda, MD 
20892, (301) 435-2037, email: [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR Panel: Academic-Industrial Partnerships for Translation 
of Technologies.
    Date: October 16, 2024.
    Time: 10:00 a.m. to 7:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Jennifer Ann Sanders, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496-3553, 
email: [email protected].

    Name of Committee: Cell Biology Integrated Review Group; Biology 
and Development of the Eye Study Section.
    Date: October 16-17, 2024.
    Time: 10:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Robert O'Hagan, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 909-6378, 
email: [email protected].

    Name of Committee: Infectious Diseases and Immunology A 
Integrated Review Group; Bacterial Virulence Study Section.
    Date: October 16-17, 2024.
    Time: 10:00 a.m. to 9:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Susan Daum, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 3202, Bethesda, MD 20892, 301-827-7233, email: 
[email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; BRAIN Initiative: Preclinical Proof of Concept for Novel 
Recording and Modulation Technologies in the Human CNS.
    Date: October 16, 2024.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Aurea D De Sousa, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5186, Bethesda, MD 20892, (301) 
827-6829, email: [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: September 12, 2024.
Bruce A. George,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-21150 Filed 9-17-24; 8:45 am]
BILLING CODE 4140-01-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.